Alfredo Arrigo Sadun | |
---|---|
Born | New Orleans, Louisiana | October 23, 1950
Nationality | American |
Occupation(s) | Ophthalmologist, academic, author and researcher |
Awards | B. Straatsma Award, AAO and AUPO for Residency Education W. Hoyt Award for Neuro-ophthalmology, AAO and NANOS Life Achievement Award, AAO Gold Medal Fellow, ARVO |
Academic background | |
Education | B.Sc., Biology Ph.D., Neuroscience M.D., Medicine |
Alma mater | Massachusetts Institute of Technology (M.I.T.) Albert Einstein College of Medicine Harvard Medical School |
Academic work | |
Institutions | UCLA School of Medicine Estelle Doheny Eye Institute |
Alfredo Arrigo Sadun (born October 23,1950) is an American ophthalmologist,academic,author and researcher. He holds the Flora L. Thornton Endowed Chair and is chief of ophthalmology at Doheny Eye Centers [1] and Vice-Chair of Ophthalmology at UCLA. [2]
Sadun has received recognition for his work in neuro-ophthalmology and especially in diseases of the optic nerve. He has published over 420 peer-reviewed articles [3] and has 5 patents awarded. He is the author of 5 books,entitled Optics for Ophthalmologists:A Board-Review Manual,Neuroprotection:Implication for Eye Disease,New Methods of Sensory Visual Testing,Ophthalmology,and Atlas of Leber’s Hereditary Optic Neuropathy. His publications have been cited about 25000 times,and his h-index is 80. [4]
Sadun is a Gold Fellow of the Association for Research in Vision and Ophthalmology (ARVO). [5] and the Editor-in-chief of Perspective for the American Academy of Ophthalmology. [6]
Sadun was born in New Orleans,LA in 1950 to Elvio Sadun a prominent parasitologist and Lina O. Sadun,a geneticist. Both were Jewish refugees who escaped Italy during the Holocaust. Sadun received his bachelor's degree in biology from the Massachusetts Institute of Technology (MIT) in 1972. He then enrolled at Albert Einstein College of Medicine,and earned a Doctoral degree in Neuroscience and a Doctorate of Medicine (MD) in 1976 and 1978,respectively. [7]
Following his Postdoctoral fellowship,Sadun held an appointment as Instructor in Ophthalmology at Harvard School of Medicine in 1983,and became Assistant Professor of Ophthalmology in the following year. In 1984,he joined the University of Southern California as an Assistant Professor,and was promoted to Associate Professor in 1987,and to Professor in 1990 and the Thornton Chair in 2000. Since 2014,he has been Professor in the Department of Ophthalmology at the University of California in Los Angeles (UCLA). [1]
He is currently the Flora L. Thornton Endowed Chair,Chief of Ophthalmology at Doheny Eye Centers-UCLA,and Vice-Chair of Ophthalmology at UCLA. [8]
Sadun organized and was the inaugural president of the Council of Program Directors for the AUPO. He was also the inaugural recipient of the AUPO/AAO's combined Straatsma Award. [9]
Sadun trained about 50 clinical and science fellows and,as director of residency training at Doheny/USC/LAC,supervised the ophthalmology training of nearly 200 residents. [10] [11]
Sadun has focused his research on diseases of the optic nerve,diseases of mitochondrial impairment,optic nerve regeneration,and neuro-protection. He has also worked and published on optic neuropathies,orbital disease,and the basic science underlying problems in neuro-ophthalmology. He has received about 20 national and international awards for his contributions to science and medicine. [12]
Sadun maintains an active laboratory at the Doheny Vision Research Center. In the 1980s,Sadun was among the pioneers to apply a new tract-tracing technique to establish nine anatomical pathways between the eye and various parts of the brain. He was the first to describe a human retinal projection to the hypothalamus that subserves the visual entrainment of the circadian rhythm. [13] In 1993,he was selected and sponsored by the United Nations to lead an investigative team to determine the cause of an epidemic of optic neuropathy in Cuba. This work led to further investigations into the role of mitochondria in optic neuropathies due to injury from nutritional,toxic,and genetic causes. The story of how Sadun led a team of investigators to solve the mystery of this blinding epidemic has been written into a book by Dr. Bruce Shields [14] [15] [16]
Sadun was the first to identify an optic neuropathy associated with Alzheimer's disease, [17] and to highlight evidence of degeneration in the optic nerves and retinas of Alzheimer Disease (AD) patients. [18] [19] He based his study on light-microscopic and ultrastructural characteristics of ganglion cell degeneration in the retinas of patients with Alzheimer's disease (AD),and found out that degeneration in the retinal ganglion cells (RGCs) is characterized by a vacuolated,‘frothy’appearance of the cytoplasm. [20] In morphometric analysis of the retinas of Alzheimer's disease patients,he demonstrated that the optic nerve initially showed predominant loss of the largest class of retinal ganglion cells (M-cells) that contribute large caliber fibers to the optic nerve. [17]
Sadun has conducted several projects regarding LHON, [21] such as gene therapy trials,small molecule therapy (eye drops and injections),histopathological analysis and a project using Artificial Intelligence with OCTA that can identify who is a carrier of LHON. With the collaboration of Valerio Carelli,studying cybrid cell cultures,they noted that the major consequence of the mitochondrial dysfunction in all three LHON mtDNA mutations was not deficiencies in ATP production,but rather great increases of reactive oxygen species (ROS). Furthermore,he has led eighteen yearly international field investigations to Brazil for studying the world's largest pedigree of LHON, [22] and established the role of environmental factors,such as heavy drinking and smoking,to trigger LHON conversion. [23] In these and other studies,he has also investigated the role of mitochondria in aging and disease in the brain,optic nerve and retina. [24]
In neuroanatomy,the optic nerve,also known as the second cranial nerve,cranial nerve II,or simply CN II,is a paired cranial nerve that transmits visual information from the retina to the brain. In humans,the optic nerve is derived from optic stalks during the seventh week of development and is composed of retinal ganglion cell axons and glial cells;it extends from the optic disc to the optic chiasma and continues as the optic tract to the lateral geniculate nucleus,pretectal nuclei,and superior colliculus.
This is a partial list of human eye diseases and disorders.
The visual field is "that portion of space in which objects are visible at the same moment during steady fixation of the gaze in one direction";in ophthalmology and neurology the emphasis is mostly on the structure inside the visual field and it is then considered “the field of functional capacity obtained and recorded by means of perimetry”.
The optic disc or optic nerve head is the point of exit for ganglion cell axons leaving the eye. Because there are no rods or cones overlying the optic disc,it corresponds to a small blind spot in each eye.
Homoplasmy is a term used in genetics to describe a eukaryotic cell whose copies of mitochondrial DNA are all identical. In normal and healthy tissues,all cells are homoplasmic. Homoplasmic mitochondrial DNA copies may be normal or mutated;however,most mutations are heteroplasmic. It has been discovered,though,that homoplasmic mitochondrial DNA mutations may be found in human tumors.
Leber's hereditary optic neuropathy (LHON) is a mitochondrially inherited degeneration of retinal ganglion cells (RGCs) and their axons that leads to an acute or subacute loss of central vision;it predominantly affects adult males,and onset is more likely in younger adults. LHON is transmitted only through the mother,as it is primarily due to mutations in the mitochondrial genome,and only the egg contributes mitochondria to the embryo. Men cannot pass on the disease to their offspring. LHON is usually due to one of three pathogenic mitochondrial DNA (mtDNA) point mutations. These mutations are at nucleotide positions 11778 G to A,3460 G to A and 14484 T to C,respectively in the ND4,ND1 and ND6 subunit genes of complex I of the oxidative phosphorylation chain in mitochondria.
Neuro-ophthalmology is an academically-oriented subspecialty that merges the fields of neurology and ophthalmology,often dealing with complex systemic diseases that have manifestations in the visual system. Neuro-ophthalmologists initially complete a residency in either neurology or ophthalmology,then do a fellowship in the complementary field. Since diagnostic studies can be normal in patients with significant neuro-ophthalmic disease,a detailed medical history and physical exam is essential,and neuro-ophthalmologists often spend a significant amount of time with their patients.
Anterior ischemic optic neuropathy (AION) is a medical condition involving loss of vision caused by damage to the anterior portion of the optic nerve as a result of insufficient blood supply (ischemia). This form of ischemic optic neuropathy is generally categorized as two types:arteritic AION,in which the loss of vision is the result of an inflammatory disease of arteries in the head called temporal arteritis,and non-arteritic AION,which is due to non-inflammatory disease of small blood vessels. It is in contrast to posterior ischemic optic neuropathy,which affects the retrobulbar portion of the optic nerve.
Dominant optic atrophy (DOA),or autosomal dominant optic atrophy (ADOA),(Kjer's type) is an autosomally inherited disease that affects the optic nerves,causing reduced visual acuity and blindness beginning in childhood. However,the disease can seem to re-present a second time with further vision loss due to the early onset of presbyopia symptoms (i.e.,difficulty in viewing objects up close). DOA is characterized as affecting neurons called retinal ganglion cells (RGCs). This condition is due to mitochondrial dysfunction mediating the death of optic nerve fibers. The RGCs axons form the optic nerve. Therefore,the disease can be considered of the central nervous system. Dominant optic atrophy was first described clinically by Batten in 1896 and named Kjer’s optic neuropathy in 1959 after Danish ophthalmologist Poul Kjer,who studied 19 families with the disease. Although dominant optic atrophy is the most common autosomally inherited optic neuropathy (i.e.,disease of the optic nerves),it is often misdiagnosed.
Toxic and nutritional optic neuropathy is a group of medical disorders defined by visual impairment due to optic nerve damage secondary to a toxic substance and/or nutritional deficiency. The causes of these disorders are various,but they are linked by shared signs and symptoms. In several of these disorders,both toxic and nutritional factors play a role,acting synergistically.
Optic neuropathy is damage to the optic nerve from any cause. The optic nerve is a bundle of millions of fibers in the retina that sends visual signals to the brain.
Allotopic expression (AE) refers to expression of genes in the cell nucleus that normally are expressed only from the mitochondrial genome. Biomedically engineered AE has been suggested as a possible future tool in gene therapy of certain mitochondria-related diseases,however this view is controversial. While this type of expression has been successfully carried out in yeast,the results in mammals have been conflicting.
Optic disc drusen (ODD) are globules of mucoproteins and mucopolysaccharides that progressively calcify in the optic disc. They are thought to be the remnants of the axonal transport system of degenerated retinal ganglion cells. ODD have also been referred to as congenitally elevated or anomalous discs,pseudopapilledema,pseudoneuritis,buried disc drusen,and disc hyaline bodies.
MT-ND6 is a gene of the mitochondrial genome coding for the NADH-ubiquinone oxidoreductase chain 6 protein (ND6). The ND6 protein is a subunit of NADH dehydrogenase (ubiquinone),which is located in the mitochondrial inner membrane and is the largest of the five complexes of the electron transport chain. Variations in the human MT-ND6 gene are associated with Leigh's syndrome,Leber's hereditary optic neuropathy (LHON) and dystonia.
MT-ND4 is a gene of the mitochondrial genome coding for the NADH-ubiquinone oxidoreductase chain 4 (ND4) protein. The ND4 protein is a subunit of NADH dehydrogenase (ubiquinone),which is located in the mitochondrial inner membrane and is the largest of the five complexes of the electron transport chain. Variations in the MT-ND4 gene are associated with age-related macular degeneration (AMD),Leber's hereditary optic neuropathy (LHON),mesial temporal lobe epilepsy (MTLE) and cystic fibrosis.
José-Alain Sahel is a French ophthalmologist and scientist. He is currently the Chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine,Director of the UPMC Vision Institute,and the Eye and Ear Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute in Paris,a research center associated with one of the oldest eye hospitals of Europe,Quinze-Vingts National Eye Hospital in Paris,founded in 1260. He is a pioneer in the field of artificial retina and eye regenerative therapies. He is a member of the French Academy of Sciences.
The Vision Institute is a research center in the Quinze-Vingts National Eye Hospital in Paris,France. It is one of several such centers in Europe on eye diseases.
Mitochondrial optic neuropathies are a heterogenous group of disorders that present with visual disturbances resultant from mitochondrial dysfunction within the anatomy of the Retinal Ganglion Cells (RGC),optic nerve,optic chiasm,and optic tract. These disturbances are multifactorial,their aetiology consisting of metabolic and/or structural damage as a consequence of genetic mutations,environmental stressors,or both. The three most common neuro-ophthalmic abnormalities seen in mitochondrial disorders are bilateral optic neuropathy,ophthalmoplegia with ptosis,and pigmentary retinopathy.
Intravitreal injection is the method of administration of drugs into the eye by injection with a fine needle. The medication will be directly applied into the vitreous humor. It is used to treat various eye diseases,such as age-related macular degeneration (AMD),diabetic retinopathy,and infections inside the eye such as endophthalmitis. As compared to topical administration,this method is beneficial for a more localized delivery of medications to the targeted site,as the needle can directly pass through the anatomical eye barrier and dynamic barrier. It could also minimize adverse drug effects on other body tissues via the systemic circulation,which could be a possible risk for intravenous injection of medications. Although there are risks of infections or other complications,with suitable precautions throughout the injection process,chances for these complications could be lowered.